Nasal Polyps – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Nasal Polyps – Pipeline Review, H2 2019’, provides an overview of the Nasal Polyps pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasal Polyps, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasal Polyps and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Nasal Polyps

– The report reviews pipeline therapeutics for Nasal Polyps by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Nasal Polyps therapeutics and enlists all their major and minor projects

– The report assesses Nasal Polyps therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Nasal Polyps”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Nasal Polyps

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nasal Polyps pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AnaptysBio Inc

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

Kyowa Kirin Co Ltd

Novartis AG

OptiNose US Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Suzhou Connect Biopharmaceuticals Ltd”

Table of Contents

Table of Contents

Introduction

Nasal Polyps (Nasal Polyposis) - Overview

Nasal Polyps (Nasal Polyposis) - Therapeutics Development

Nasal Polyps (Nasal Polyposis) - Therapeutics Assessment

Nasal Polyps (Nasal Polyposis) - Companies Involved in Therapeutics Development

Nasal Polyps (Nasal Polyposis) - Drug Profiles

Nasal Polyps (Nasal Polyposis) - Dormant Projects

Nasal Polyps (Nasal Polyposis) - Discontinued Products

Nasal Polyps (Nasal Polyposis) - Product Development Milestones

Appendix

List of Tables

“List of Tables

Table 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Products under Development by Companies, H2 2019

Table 4: Number of Products by Stage and Target, H2 2019

Table 5: Number of Products by Stage and Mechanism of Action, H2 2019

Table 6: Number of Products by Stage and Route of Administration, H2 2019

Table 7: Number of Products by Stage and Molecule Type, H2 2019

Table 8: Nasal Polyps (Nasal Polyposis) – Pipeline by AnaptysBio Inc, H2 2019

Table 9: Nasal Polyps (Nasal Polyposis) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Table 10: Nasal Polyps (Nasal Polyposis) – Pipeline by GlaxoSmithKline Plc, H2 2019

Table 11: Nasal Polyps (Nasal Polyposis) – Pipeline by Idorsia Pharmaceutical Ltd, H2 2019

Table 12: Nasal Polyps (Nasal Polyposis) – Pipeline by Kyowa Kirin Co Ltd, H2 2019

Table 13: Nasal Polyps (Nasal Polyposis) – Pipeline by Novartis AG, H2 2019

Table 14: Nasal Polyps (Nasal Polyposis) – Pipeline by OptiNose US Inc, H2 2019

Table 15: Nasal Polyps (Nasal Polyposis) – Pipeline by Pfizer Inc, H2 2019

Table 16: Nasal Polyps (Nasal Polyposis) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Table 17: Nasal Polyps (Nasal Polyposis) – Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H2 2019

Table 18: Nasal Polyps (Nasal Polyposis) – Dormant Projects, H2 2019

Table 19: Nasal Polyps (Nasal Polyposis) – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products by Targets, H2 2019

Figure 4: Number of Products by Stage and Targets, H2 2019

Figure 5: Number of Products by Mechanism of Actions, H2 2019

Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019

Figure 7: Number of Products by Routes of Administration, H2 2019

Figure 8: Number of Products by Stage and Routes of Administration, H2 2019

Figure 9: Number of Products by Molecule Types, H2 2019

Figure 10: Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared